Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104741 | 0.94 | TSHR (0.35) | TSHRALDH1A1CYP3A4HIF1AADRB2 | |
| SCHEMBL22389044 | 0.87 | ALDH1A1 (0.38) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL24199120 | 0.84 | ALDH1A1 (0.44) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL17298943 | 0.84 | ALDH1A1 (0.30) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL21788095 | 0.83 | ADRB2 (0.36) | TSHRALDH1A1CYP3A4HIF1AADRB2 | |
| SCHEMBL23945844 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL17624872 | 0.80 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL3838045 | 0.80 | TSHR (0.64) | TSHRALDH1A1CYP3A4HIF1A | |
| SCHEMBL12425858 | 0.78 | ALDH1A1 (0.31) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL23550067 | 0.77 | TSHR (0.32) | TSHRALDH1A1CYP3A4HIF1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | TSHR 1797/4885ALDH1A1 1130/4885CYP3A4 1679/4885 |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | TSHR 3166/4885ALDH1A1 618/4885CYP3A4 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.